Magnesium Hydride Protects Lungs from Severe Respiratory Distress
- Authors
- Xuan Shi, Lina Zhu, Sheng Wang, Wanli Zhu, Quanfu Li, Juan Wei, Di Feng, Meiyun Liu, Yuanli Chen, Xuejun Sun, Hongtao Lu, Xin Lv
- Journal
- Oxidative Medicine and Cellular Longevity
- Year
- 2022
- DOI
- 10.1155/2022/5918954
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Acute Respiratory Distress Syndrome
- Body System
- Respiratory
TL;DR
Magnesium hydride (MgH2) could potentially help treat a severe lung condition called ARDS by reducing inflammation, oxidative damage, cell death, and improving lung cell barriers.
Key Finding
Magnesium hydride reduced inflammation, oxidative stress, and cell death in laboratory and animal models of acute respiratory distress syndrome, with treated mice showing improved survival rates and less lung damage.
Summary
This study tested whether magnesium hydride (a compound that releases hydrogen) could protect against acute respiratory distress syndrome (ARDS), a serious lung condition involving severe inflammation. Using lab cells and mice, researchers found that magnesium hydride reduced inflammation, decreased harmful molecules called free radicals, prevented cell death, and strengthened the barrier that lines the lungs—all effects that improved survival in treated mice.
Practical Takeaway
While this early-stage research in cells and mice suggests hydrogen-releasing compounds may have protective effects in severe lung disease, these findings cannot yet be applied to humans. Much more research, including human clinical trials, would be needed before any therapeutic claims could be made about hydrogen water or magnesium hydride for respiratory health.
Abstract
Acute respiratory distress syndrome (ARDS) causes uncontrolled pulmonary inflammation, resulting in high morbidity and mortality in severe cases. Given the antioxidative effect of molecular hydrogen, some recent studies suggest the potential use of molecular hydrogen as a biomedicine for the treatment of ARDS. In this study, we aimed to explore the protective effects of magnesium hydride (MgH2) on two types of ARDS models and its underlying mechanism in a lipopolysaccharide (LPS)-induced ARDS model of the A549 cell line. The results showed that LPS successfully induced oxidative stress, inflammatory reaction, apoptosis, and barrier breakdown in alveolar epithelial cells (AEC). MgH2 can exert an anti-inflammatory effect by down-regulating the expressions of inflammatory cytokines (IL-1β, IL-6, and TNF-α). In addition, MgH2 decreased oxidative stress by eliminating intracellular ROS, inhibited apoptosis by regulating the expressions of cytochrome c, Bax, and Bcl-2, and suppressed barrier breakdown by up-regulating the expression of ZO-1 and occludin. Mechanistically, the expressions of p-AKT, p-mTOR, p-P65, NLRP3, and cleaved-caspase-1 were decreased after MgH2 treatment, indicating that AKT/mTOR and NF-κB/NLRP3/IL-1β pathways participated in the protective effects of MgH2. Furthermore, the in vivo study also demonstrated that MgH2-treated mice had a better survival rate and weaker pathological damage. All these findings demonstrated that MgH2 could exert an ARDS-protective effect by regulating the AKT/mTOR and NF-κB/NLRP3/IL-1β pathways to suppress LPS-induced inflammatory reaction, oxidative stress injury, apoptosis, and barrier breakdown, which may provide a potential strategy for the prevention and treatment of ARDS.